[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
January 5, 2000

Incorrect Wording

JAMA. 2000;283(1):57. doi:10.1001/jama.283.1.57

In the Letter entitled "Relapse of Depressive Symptoms After Discontinuing Sertraline," published in the July 28, 1999, issue of THE JOURNAL (1999;282:323-324), the financial disclosure statement for the reply letter is incomplete. The following should be added to what was published: "Drs Gelenberg, Rush, Koran, Klein, McCullough, Kocsis, Kornstein, Schatzberg, and Fawcett have served as consultants to and/or received grant support from numerous pharmaceutical companies, some of which manufacture sertraline or other selective serotonin reuptake inhibitors. In addition, Drs Gelenberg, Kocsis, and Schatzberg own stock in 1 or more companies that manufacture sertraline or other selective serotonin reuptake inhibitors, and Dr LaVange is affiliated with Quintiles Inc, a for-profit contract research organization, and in that role provides statistical consulting for many pharmaceutical companies, including Pfizer Inc."

×